ImmunityBio (IBRX) is jumping 20% after the drug maker reported that the FDA had approved its use of an “alternative source ...

We recently published a list of 10 Stocks Stand Strong Amid Cautious Market Environment. In this article, we are going to ...

ImmunityBio (IBRX) announced the U.S. Food and Drug Administration FDA has authorized an expanded access program EAP that will bring a vital ...

CULVER CITY, Calif., February 19, 2025--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA) has authorized an expanded ...

ImmunityBio, Inc. (NASDAQ:IBRX) is a biotechnology company working to develop therapies that enhance the immune system of patients, instead of weakening it. Since its inception in 2014 ...

D. Boral Capital restated their buy rating on shares of ImmunityBio (NASDAQ:IBRX – Free Report) in a report released on Friday,Benzinga reports. They currently have a $30.00 price target on the stock.

The firm decreased its portfolio allocation in IBRX by 24.70% over the last quarter. XBI - SPDR(R) S&P(R) Biotech ETF holds 5,238K shares representing 0.75% ownership of the company. In its prior ...

IonQ, H&E Equipment Services And ImmunityBio Are Among Top Mid Cap Gainers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio? Explore this week's top-performing mid-cap stocks, including ...

ImmunityBio (IBRX) announced the Medicines and Healthcare products Regulatory Agency has validated and accepted the marketing authorization ...